News

Koa Health secures over €14m initial funding and spins out of Telefónica’s moonshot factory

Details

The funding round led by Ancora Finance Group and Wellington Partners will bolster Koa Health’s growth ambitions to make mental health treatment more accessible with its wide range of digital solutions. 

Digital therapeutics leader Sidekick raises $20M in Series A funding round led by Wellington and Asabys

Details

Nordic digital therapeutics company Sidekick Health has completed a $20 million oversubscribed Series A financing round led by Wellington Partners and Asabys Partners, through its fund SAHII, with participation by existing investors Novator and Frumtak Ventures.  

CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy

Details

CARISMA Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). Under this IND, CARISMA intends to initiate its Phase 1, first-in-human, multi-center study in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2 targeted agents. 

  1. Immatics announces completion of business combination and listing on NASDAQ
  2. SIRS Therapeutics: F4 Pharma’s FX06 shows promising results in critically ill COVID-19 patients
  3. Confo Therapeutics expands board with appointment of Rob Scott as Independent Director
  4. GTX Medical was granted FDA Breakthrough Device Designation for Go-2 Targeted Epidural Spinal Stimulation (TESS) system
© Wellington Partners, 2021.